THE WOODLANDS, Texas, May 27 /PRNewswire-FirstCall/ --Lexicon Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that the company will be giving oral presentations on two of its clinical-stage drug development programs: LX1031, an oral drug candidate for the treatment of irritable bowel syndrome (IBS), and LX1032, an oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. The presentations will take place at Digestive Disease Week (DDW) in Chicago, Illinois on Sunday, May 31 and Monday, June 1, respectively. DDW is the world’s largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. LX1031 is currently in a Phase 2 clinical trial in patients with non-constipating IBS, and LX1032 is entering a Phase 2 study in patients with carcinoid syndrome.
For more information on these programs and to download both presentations (available after June 1), please visit www.lexpharma.com.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company’s research team. The company has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s clinical development of LX1031 and LX1032 and the potential therapeutic and commercial potential of LX1031 and LX1032. This press release also contains forward-looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon’s ability to successfully conduct clinical development of LX1031 and LX1032 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Factors Affecting Forward-Looking Statements” and “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Jason Ray, Manager, Corporate Communications and Investor
Relations of Lexicon Pharmaceuticals, Inc., +1-281-863-3225,
jray@lexpharma.com
Web site: http://www.lexpharma.com/
